Related Experiment Video
Updated: Jul 20, 2025
07:28
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
40.8K
Ensifentrine as a Novel, Inhaled Treatment for Patients with COPD
James F Donohue1, Tara Rheault2, Margot MacDonald-Berko2
1Division of Pulmonary and Critical Care Medicine, University of North Carolina, School of Medicine, Chapel Hill, NC, USA.
Summary
Ensifentrine, a dual phosphodiesterase (PDE)3 and PDE4 inhibitor, shows promise for COPD maintenance treatment. It improves lung function, symptoms, and quality of life through inhalation therapy.
Area of Science:
- Pharmacology
- Respiratory Medicine
Background:
- Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disease characterized by persistent respiratory symptoms and airflow limitation.
- Current treatments aim to reduce symptoms and exacerbations but often have limitations.
Purpose of the Study:
- To review non-clinical data and Phase 1/2 clinical trial results for nebulized ensifentrine.
- To evaluate ensifentrine's efficacy and safety for COPD maintenance treatment.
Main Methods:
- Ensifentrine is a novel inhaled dual inhibitor of phosphodiesterase (PDE)3 and PDE4.
- Phase 1 and Phase 2 clinical studies were conducted in COPD patients.
Main Results:
- Ensifentrine demonstrated potent and selective inhibition of PDE3 and PDE4.
- Phase 2 studies showed clinically meaningful bronchodilation and improvements in COPD symptoms and quality of life.
- Positive safety profile observed when administered alone or with standard therapies.
Conclusions:
- Nebulized ensifentrine offers a multi-faceted approach to COPD management by targeting inflammation, bronchodilation, and ciliary function.
- Ensifentrine shows potential as an effective and safe maintenance therapy for COPD patients.
Related Concept Videos
01:23Inhaled Medications
311
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
311
01:26COPD: Management Using Bronchodilators and Corticosteroids
244
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
244
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
300
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
300
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
215
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
215
01:17Drugs Used in Lower Respiratory Disorders: Overview
489
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
489
01:30Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K